LEARN ABOUT THIS STUDY – WITH STUDY CENTERS IN USA AND OUTSIDE OF USA HERE: Theravance Biopharma is researching the investigational drug (ampreloxetine) because they believe it may reduce nOH symptoms that interfere with daily activity in MSA patients based on prior clinical trial results. They are running the Phase 3 CYPRESS trial to […]

Dr Patrik Brundin appointed to leadership role at Roche Global

We are delighted to hear that Dr Patrik Brundin, a strong advocate for the MSA cause and a dear friend to Defeat MSA Alliance (US) and our affiliated partners in the MSA United Consortium has been appointed to a top level position at Roche Global, the largest pharmaceutical company in the world. Dr Brundin will […]